Milne A, Brawner T A, Dumbill P C, Kawachi I, Pearce N E
Hepatitis Research Unit, Whakatane Hospital, Whakatane, New Zealand.
J Med Virol. 1989 Mar;27(3):264-7. doi: 10.1002/jmv.1890270314.
A group of 201 hepatitis B virus (HBV) sero-negative children 1-12 years of age received either three 2 micrograms doses of Merck Sharp and Dohme (MSD) or Smith Kline and French (SKF) recombinant DNA (rDNA) hepatitis B vaccine I.M. at monthly intervals. Each recipient was tested 4-6 weeks later for antibody to hepatitis B surface antigen (anti-HBs) by enzyme immunoassay (EIA) and radioimmunoassay (RIA). Ninety-six 4-5-year-old children, given 2 micrograms doses of a plasma-derived vaccine (MSD, H-B-Vax) I.M. at 0, 1, 2 months, were tested at the same time with the same assays for comparison. Anti-HBs responses and geometric mean titres (GMT) were significantly higher with the MSDrDNA vaccine (96% and 338.9 IU/liter) than with the SKF/r DNA vaccine (82.3% and 69.4 IU/liter). We conclude that for the protection of young children, 2 micrograms doses of the MSD rDNA hepatitis B vaccine may be used under similar circumstances in which 2 micrograms of the MSD plasma-derived vaccine was used. Further studies are needed before the other rDNA hepatitis B vaccine may be used in lower than the 10 micrograms dose recommended in children.
一组201名1至12岁的乙型肝炎病毒（HBV）血清学阴性儿童，分别接受了默克雪兰诺公司（MSD）或史克必成公司（SKF）的重组DNA（rDNA）乙型肝炎疫苗，每次2微克，共3剂，肌肉注射，间隔1个月。在4至6周后，通过酶免疫测定法（EIA）和放射免疫测定法（RIA）对每位接种者进行乙型肝炎表面抗原抗体（抗-HBs）检测。同时，对96名4至5岁的儿童进行检测并比较，这些儿童在0、1、2个月时肌肉注射了2微克剂量的血浆源性疫苗（MSD，H-B-Vax）。MSD的rDNA疫苗的抗-HBs反应和几何平均滴度（GMT）（分别为96%和338.9 IU/升）显著高于SKF/rDNA疫苗（分别为82.3%和69.4 IU/升）。我们得出结论，为保护幼儿，在可使用2微克MSD血浆源性疫苗的类似情况下，可使用2微克剂量的MSD rDNA乙型肝炎疫苗。在其他rDNA乙型肝炎疫苗可用于低于儿童推荐的10微克剂量之前，还需要进一步研究。
